Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target
Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...
Investing News Network on MSN4d
Biotech Market Forecast: Top Trends for Biotech in 2025
The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...
Chemistry World4d
J&J’s Intra-Cellular deal could signal more mega-mergers for 2025
The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...
Odyssey Therapeutics Begins IPO Rollout
Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...
Two Massachusetts biotechs file to IPO post-JPM
A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...
FierceBiotech5d
Odyssey, Sionna join band of biotechs ready to brave thawing IPO waters in 2025
Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...